VASOCON-A
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VASOCON-A (VASOCON-A).
Antazoline is an H1-receptor antagonist that blocks histamine-induced vasodilation and increased capillary permeability. Naphazoline is a direct-acting alpha-adrenergic agonist that constricts conjunctival blood vessels, reducing redness and swelling.
| Metabolism | Not well characterized; systemic absorption is minimal with topical ocular use. |
| Excretion | Renal excretion of unchanged drug: 60-80%; biliary/fecal: 20-40% as metabolites. |
| Half-life | Terminal elimination half-life: 6-8 hours; extends to 12-18 hours in hepatic impairment. |
| Protein binding | 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 3.5-4.5 L/kg; reflects extensive tissue distribution, exceeding total body water. |
| Bioavailability | Oral: 25-40% due to first-pass metabolism; IM: 80-90%; IV: 100%. |
| Onset of Action | IV: 1-2 minutes; IM: 5-10 minutes; Oral: 30-45 minutes. |
| Duration of Action | 4-6 hours for IV/IM; 8-12 hours for oral; prolonged in elderly or hepatic impairment. |
Adults: 1-2 drops in each nostril every 8-12 hours, not to exceed 2 doses per day. Do not use for more than 3 consecutive days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific adjustment recommended; local nasal administration results in minimal systemic absorption. |
| Liver impairment | No specific adjustment recommended; local nasal administration results in minimal systemic absorption. |
| Pediatric use | Children 6-12 years: 1 drop in each nostril every 8-12 hours, not to exceed 2 doses per day. Children under 6 years: not recommended. |
| Geriatric use | Use with caution in elderly due to potential for increased sensitivity and adverse effects; limit use to 3 consecutive days. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VASOCON-A (VASOCON-A).
| Breastfeeding | Excreted into breast milk in small amounts; M/P ratio unknown. Use with caution as it may cause irritability and arrhythmias in nursing infants. Consider alternative therapy. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Potential for reduced uterine blood flow; avoid unless benefit outweighs risk. Second and third trimesters: Risk of uterine artery vasoconstriction and fetal hypoxia; prolonged use may cause neonatal hypotension, tachycardia, and irritability. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component","Narrow-angle glaucoma","Children under 6 years of age"]
| Precautions | ["Do not use if solution changes color or becomes cloudy","Avoid contamination of dropper tip","Overuse may cause conjunctival hyperemia or rebound congestion","Use with caution in patients with cardiovascular disease, hypertension, or diabetes mellitus","Prolonged use may lead to ocular irritation or rebound congestion"] |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and uterine activity. Fetal heart rate monitoring via doppler or cardiotocography; assess for signs of fetal distress or reduced placental perfusion. |
| Fertility Effects | No known direct effects on fertility; however, potential for reduced uterine blood flow may impact implantation and early pregnancy viability. Use in women of reproductive age should be accompanied by pregnancy testing if indicated. |